1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. New Products | 新产品
  5. NEW1
  6. New1

Lactose, anhydrous

别名: Lactose, anhydrous Lactose Galactinum Fast-flo 乳糖; 无水乳糖; 药用乳糖; D-乳糖;一水合乳糖; 乳糖(一水);乳糖,无水;乳糖(AR);D(+)-乳糖;β乳糖;β乳糖,药用级;乳糖 标准品;乳糖（无水）;乳糖(无水) EP标准品;无水乳糖 USP标准品;无水乳糖,AR;无水乳糖标准品(JP);一水乳糖;乳糖,无水,Lactosum , anhydrous,AR;乳糖,无水,Lactosum , anhydrous,Ph Eur,USP,NF,JP;压片粘合剂
目录号: V5974 纯度: ≥98%
COA 产品数据 产品说明书 SDS
乳糖是大多数物种乳汁中的主要糖分，可调节人类肠道的微生物菌群。
Lactose, anhydrous CAS号: 63-42-3
产品类别: New1
产品仅用于科学研究，不针对患者销售
规格 价格 库存 数量
50mg
100mg
250mg
500mg
1g
Other Sizes
加入购物车 结帐 大包装询价
020-31522723 sales@invivochem.cn
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
产品描述
乳糖是大多数物种乳汁中的主要糖类，它能调节人类肠道的微生物菌群。
生物活性&实验参考方法
体内研究 (In Vivo)
本研究探讨了乳糖摄入对老年便秘患者排便习惯的影响。研究纳入15名女性受试者，平均年龄76.4岁。受试者食用添加了乳糖的常规医院膳食。给药方案为：每日20克，持续8天；随后进行3天适应期，剂量逐步增加至每日40克；之后从第12天至第19天维持该剂量。20克剂量于上午8:00一次性服用，溶于250毫升水中；40克剂量分两次服用，每次20克，分别于上午8:00和下午4:00服用。受试者对乳糖的反应差异很大。15名受试者中有4名，每日20克乳糖使排便次数增加至每周3-4次，而每日40克乳糖则进一步使排便次数增加至每周7.5次。在另外七名受试者中，仅每日20克剂量组的排便频率增加（至每日一次），而每日40克剂量组则减少至每周2-3次，导致大便变硬并出现排便困难。这七名患者中有四名报告有中度腹痛。四名受试者无论剂量如何，仅出现轻微的通便作用（每周排便2-3次），并抱怨胀气严重。每日摄入20克乳糖后，粪便干物质百分比较基线显著下降（从32.3% ± 6.3%降至28.4% ± 6.4%，p<0.05），每日40克剂量组也观察到类似效果（27.3% ± 5.5%，p<0.05），这与粪便含水量增加相对应[1]。
酶活实验
粪便β-葡萄糖苷酶和β-葡萄糖醛酸酶活性分别通过光度法测定，即监测显色底物对硝基苯基-β-吡喃葡萄糖苷和对硝基苯基-β-D-葡萄糖醛酸苷的水解情况。酶活性表示为在37℃下，每毫克粪便干重每分钟水解1 μmol底物所需的酶量。与基线水平相比，饲喂20 g/d或40 g/d乳糖后，这些酶的粪便活性均未观察到显著变化[1]。
药代性质 (ADME/PK)
乳糖是一种双糖，可被结肠微生物群利用进行发酵。这种情况主要发生在特定双糖缺乏、相应转运系统缺陷，或摄入的糖量超过小肠最大吸收速率时，导致糖溢出到大肠[1]。
毒性/毒理 (Toxicokinetics/TK)
相互作用
与喂食基础蔗糖饮食的对照组相比，喂食含40%乳糖饮食5天的大鼠肝脏总胆固醇水平更高。添加乳糖的饮食显著降低了粪便甾醇的产生，提示该结果可能与胆固醇吸收有关。定量平衡研究表明，蔗糖对照组吸收了40.4%的胆固醇，而乳糖组吸收了相同剂量的66.2%。当饮食中添加乳糖时，2%和4%的氯化钙均能抑制胆固醇的吸收；然而，当添加蔗糖时，需要高达4%的氯化钙才能产生类似的效果……
老年便秘患者服用乳糖作为膳食补充剂会产生一些不良反应。虽然20克/天的剂量对某些患者有通便作用，但40克/天的较高剂量却导致部分患者出现大便干结和排便困难。此外，部分患者还报告了胀气、肠胀气和腹痛等副作用。具体而言，15名患者中有4名抱怨胀气严重，另有4名报告在摄入乳糖期间出现中度腹痛[1]。
参考文献

[1]. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr. 1997 May;65(5):1397-402.
其他信息
乳糖是一种白色、坚硬的结晶粉末。(NTP, 1992)
β-乳糖是乳糖的β-异构体。
它是一种由葡萄糖和半乳糖组成的二糖，存在于人乳和牛乳中。它被用作制药片剂、医药营养剂和工业原料。
据报道，圣约翰草含有β-乳糖，并且有相关数据支持。
它是一种由葡萄糖和半乳糖组成的二糖，存在于人乳和牛乳中。它被用作制药片剂、医药营养剂和工业原料。
历史上，乳糖一直被推荐用于治疗多种胃肠道疾病，包括便秘。本研究探讨了乳糖治疗便秘的疗效，并将其与菊粉进行了比较。研究证实，老年患者的肠道菌群会受到乳糖摄入的影响。在摄入乳糖的个体中，检测到粪便中肠球菌数量显著增加（从 log₁₀ 7.1 ± 1.1 增加到 8.1 ± 1.2 CFU/g 干粪，p<0.01），而乳杆菌（从 log₁₀ 7.9 ± 0.9 减少到 7.0 ± 1.0 CFU/g 干粪，p<0.05）和梭菌（从 log₁₀ 6.4 ± 1.2 减少到 5.6 ± 0.8 CFU/g 干粪，p<0.05）数量则显著减少。在 15 名每日摄入 40 克乳糖的患者中，有 5 名患者的拟杆菌属数量增加了约 2 个对数级。该研究表明，乳糖的通便作用在个体间差异很大，并且可能伴有明显的不适感[1]。
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
精确质量
342.116
CAS号
63-42-3
PubChem CID
6134
外观&性状
White, hard, crystalline mass of white powder
密度
1.8±0.1 g/cm3
沸点
667.9±55.0 °C at 760 mmHg
熔点
222.8°C
闪点
357.8±31.5 °C
蒸汽压
0.0±4.6 mmHg at 25°C
折射率
1.652
LogP
-3.41
tPSA
197.37
氢键供体(HBD)数目
8
氢键受体(HBA)数目
11
可旋转键数目(RBC)
4
重原子数目
23
分子复杂度/Complexity
382
定义原子立体中心数目
10
SMILES
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O
InChi Key
GUBGYTABKSRVRQ-DCSYEGIMSA-N
InChi Code
InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1
化学名
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
别名
Lactose, anhydrous Lactose Galactinum Fast-flo
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
H2O : ~100 mg/mL (~292.14 mM)
DMSO : ~50 mg/mL (~146.07 mM)
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.5 mg/mL (7.30 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。
配方 2 中的溶解度: ≥ 2.5 mg/mL (7.30 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。
View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (7.30 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

配方 4 中的溶解度: 130 mg/mL (379.78 mM) in PBS (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液; 超声助溶.

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
Title:Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumption
Status:Completed
updateDate:2026-05-01
Ctid:NCT06724705

Link: https://clinicaltrials.gov/ct2/show/NCT06724705

Conditions:Lactose Intolerance, Adult Type
Interventions:Sucrose
Phase:N/A
Title:Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)
Status:Completed
updateDate:2026-04-17
Ctid:NCT02584439

Link: https://clinicaltrials.gov/ct2/show/NCT02584439

Conditions:Healthy|Vascular Stiffness|Aging
Interventions:lactose capsule (placebo)
Phase:Phase 3
Title:PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
Status:Completed
updateDate:2025-12-04
Ctid:NCT03582176

Link: https://clinicaltrials.gov/ct2/show/NCT03582176

Conditions:Elbow Fracture|Elbow Injury|Elbow Dislocation
Interventions:Ketotifen Fumarate 5mg
Phase:Phase 3
View More

Title:Human Cerebral Blood Flow Regulation
Status:Completed
updateDate:2025-10-03
Ctid:NCT04265053

Link: https://clinicaltrials.gov/ct2/show/NCT04265053

Conditions:Cerebral Arterial Diseases
Interventions:Antacid
Phase:Early Phase 1
Title:Evaluating the Impact of Synbiotic Supplementation on Infants and Toddlers
Status:Active, not recruiting
updateDate:2025-09-10
Ctid:NCT06746285

Link: https://clinicaltrials.gov/ct2/show/NCT06746285

Conditions:Gastrointestinal Tolerance of Probiotics in Infants
Interventions:Lactose (inactive placebo)
Phase:N/A
Title:Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
Status:Completed
updateDate:2024-10-31
Ctid:NCT01404754

Link: https://clinicaltrials.gov/ct2/show/NCT01404754

Conditions:Psychological Effects of Study Drug
Interventions:midomafetamine HCl
Phase:Phase 1
Title:Effect of Lactose on Blood Lipids
Status:Completed
updateDate:2024-09-23
Ctid:NCT04924530

Link: https://clinicaltrials.gov/ct2/show/NCT04924530

Conditions:Cardiovascular Risk Factor|Lipaemia|Metabolic Disease
Interventions:Lactose
Phase:N/A
Title:Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial (LiFT)
Status:Unknown status
updateDate:2024-01-26
Ctid:NCT02999022

Link: https://clinicaltrials.gov/ct2/show/NCT02999022

Conditions:Fractures
Interventions:Lactose Placebo
Phase:Phase 2
Title:Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Status:Withdrawn
updateDate:2022-06-03
Ctid:NCT00888680

Link: https://clinicaltrials.gov/ct2/show/NCT00888680

Conditions:Migraine
Interventions:Lactose
Phase:Phase 2
Title:Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
Status:Completed
updateDate:2021-05-10
Ctid:NCT01041755

Link: https://clinicaltrials.gov/ct2/show/NCT01041755

Conditions:Hepatic Encephalopathy
Interventions:Lactose
Phase:Phase 4
Title:Preventing Recurrent Urinary Tract Infections With α-D-mannose
Status:Terminated
updateDate:2020-09-02
Ctid:NCT03497598

Link: https://clinicaltrials.gov/ct2/show/NCT03497598

Conditions:Urinary Tract Infections
Interventions:Lactose
Phase:Phase 4
Title:SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation
Status:Terminated
updateDate:2019-10-01
Ctid:NCT01434745

Link: https://clinicaltrials.gov/ct2/show/NCT01434745

Conditions:Smith-Lemli-Opitz Syndrome
Interventions:Lactose
Phase:N/A
Title:DAS181 Single Dose Escalation Study in Healthy Adults
Status:Completed
updateDate:2019-08-02
Ctid:NCT00876161

Link: https://clinicaltrials.gov/ct2/show/NCT00876161

Conditions:Healthy
Interventions:Lactose
Phase:Phase 1
Title:Therapeutic Lactose to Support Vaginal Microbiota
Status:Completed
updateDate:2019-03-19
Ctid:NCT03878511

Link: https://clinicaltrials.gov/ct2/show/NCT03878511

Conditions:Bacterial Vaginoses
Interventions:Placebo
Phase:N/A
Title:Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'
Status:Completed
updateDate:2018-03-20
Ctid:NCT01550107

Link: https://clinicaltrials.gov/ct2/show/NCT01550107

Conditions:Sarcopenia
Interventions:Lactose tablets
Phase:Phase 4
Title:A Dietary Supplement for Early Cigarette Withdrawal
Status:Completed
updateDate:2018-02-14
Ctid:NCT02042521

Link: https://clinicaltrials.gov/ct2/show/NCT02042521

Conditions:Nicotine Dependence, Cigarettes, With Withdrawal
Interventions:Lactose Placebo
Phase:Phase 2
Title:A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Status:Completed
updateDate:2017-09-25
Ctid:NCT01644877

Link: https://clinicaltrials.gov/ct2/show/NCT01644877

Conditions:Parainfluenza
Interventions:Lactose Placebo
Phase:Phase 2
Title:Orall Administered Probiotics to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.
Status:Completed
updateDate:2017-06-06
Ctid:NCT01723592

Link: https://clinicaltrials.gov/ct2/show/NCT01723592

Conditions:Breast Cancer
Interventions:Oral lactose placebo
Phase:N/A
Title:The Effects of N-acetylcysteine on Performance and Redox Homeostasis
Status:Completed
updateDate:2017-04-21
Ctid:NCT03121222

Link: https://clinicaltrials.gov/ct2/show/NCT03121222

Conditions:Glutathione Metabolism Anemias
Interventions:Lactose
Phase:Phase 2
Title:Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance
Status:Completed
updateDate:2016-12-28
Ctid:NCT02636413

Link: https://clinicaltrials.gov/ct2/show/NCT02636413

Conditions:Lactose Intolerance
Interventions:lactose
Phase:Phase 4
Title:Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score
Status:Completed
updateDate:2016-10-11
Ctid:NCT01675986

Link: https://clinicaltrials.gov/ct2/show/NCT01675986

Conditions:Feeling Anxious
Interventions:Lactose
Phase:Phase 2
Title:Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting
Status:Completed
updateDate:2016-06-03
Ctid:NCT02787707

Link: https://clinicaltrials.gov/ct2/show/NCT02787707

Conditions:Nausea|Vomiting
Interventions:lactose
Phase:Phase 2
Title:Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive
Status:Completed
updateDate:2016-05-20
Ctid:NCT02566798

Link: https://clinicaltrials.gov/ct2/show/NCT02566798

Conditions:Osteoarthritis
Interventions:Lactose
Phase:N/A
Title:Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers
Status:Completed
updateDate:2016-04-01
Ctid:NCT02596360

Link: https://clinicaltrials.gov/ct2/show/NCT02596360

Conditions:Experimental Pain|Hyperalgesia
Interventions:lactose
Phase:Phase 1
Title:The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements
Status:Completed
updateDate:2015-05-20
Ctid:NCT02448940

Link: https://clinicaltrials.gov/ct2/show/NCT02448940

Conditions:Overweight and Obesity
Interventions:lactose
Phase:N/A
Title:Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery?
Status:Completed
updateDate:2014-10-13
Ctid:NCT01848119

Link: https://clinicaltrials.gov/ct2/show/NCT01848119

Conditions:Pain
Interventions:lactose
Phase:N/A
Title:Glucosamine Periodontal Adjunctive Therapy
Status:Terminated
updateDate:2014-08-12
Ctid:NCT02214095

Link: https://clinicaltrials.gov/ct2/show/NCT02214095

Conditions:Chronic Periodontitis
Interventions:lactose capsules
Phase:Early Phase 1
Title:Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
Status:Terminated
updateDate:2014-06-24
Ctid:NCT02172508

Link: https://clinicaltrials.gov/ct2/show/NCT02172508

Conditions:Pulmonary Disease, Chronic Obstructive
Interventions:Placebo Lactose Capsule
Phase:Phase 4
Title:Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
Status:Terminated
updateDate:2014-03-28
Ctid:NCT00980031

Link: https://clinicaltrials.gov/ct2/show/NCT00980031

Conditions:Myocardial Remodeling
Interventions:Lactose Tablet
Phase:N/A
Title:The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:Completed
updateDate:2014-03-24
Ctid:NCT01151306

Link: https://clinicaltrials.gov/ct2/show/NCT01151306

Conditions:Chronic Obstructive Pulmonary Disease
Interventions:Lactose tablet
Phase:Phase 4
Title:The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
Status:Completed
updateDate:2014-01-23
Ctid:NCT01277237

Link: https://clinicaltrials.gov/ct2/show/NCT01277237

Conditions:Non Alcoholic Fatty Liver Disease
Interventions:lactose tablet
Phase:Phase 3
Title:Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin
Status:Completed
updateDate:2013-11-08
Ctid:NCT00979056

Link: https://clinicaltrials.gov/ct2/show/NCT00979056

Conditions:Diarrhoea
Interventions:Lactose
Phase:Phase 3
Title:Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT
Status:Completed
updateDate:2013-05-06
Ctid:NCT00624754

Link: https://clinicaltrials.gov/ct2/show/NCT00624754

Conditions:Obstructive Airway Disease
Interventions:lactose
Phase:Phase 2
Title:The Effects of Atorvastatin Treatment in COPD Patients
Status:Completed
updateDate:2013-04-23
Ctid:NCT01748279

Link: https://clinicaltrials.gov/ct2/show/NCT01748279

Conditions:COPD
Interventions:Lactose tablet
Phase:Phase 4
Title:Mechanism of Action of Milk and Its Components on Glycemic Control in Healthy Young Men
Status:Completed
updateDate:2013-03-18
Ctid:NCT01812967

Link: https://clinicaltrials.gov/ct2/show/NCT01812967

Conditions:Glycemic Control|Gastrointestinal Hormone Response|Healthy Young Men
Interventions:Simulated Milk Beverage
Phase:N/A
Title:The Effect of Melatonin on Nocturnal Enuresis
Status:Unknown status
updateDate:2012-11-02
Ctid:NCT01575678

Link: https://clinicaltrials.gov/ct2/show/NCT01575678

Conditions:Nocturnal Enuresis
Interventions:Lactose
Phase:Phase 2
Title:Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Status:Completed
updateDate:2012-06-08
Ctid:NCT01028014

Link: https://clinicaltrials.gov/ct2/show/NCT01028014

Conditions:Urethral Sphincter Activity
Interventions:Solifenacin
Phase:N/A
Title:Cholecalciferol Supplementation, Muscle Strength
Status:Completed
updateDate:2011-06-15
Ctid:NCT00682214

Link: https://clinicaltrials.gov/ct2/show/NCT00682214

Conditions:Vitamin D Deficiency
Interventions:Lactose placebo
Phase:Phase 1
Title:The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section
Status:Completed
updateDate:2011-02-23
Ctid:NCT01094925

Link: https://clinicaltrials.gov/ct2/show/NCT01094925

Conditions:Pain
Interventions:Gabapentin 600mg
Phase:N/A
Title:Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects
Status:Completed
updateDate:2010-09-24
Ctid:NCT01136317

Link: https://clinicaltrials.gov/ct2/show/NCT01136317

Conditions:Gastroesophageal Reflux
Interventions:Lactose
Phase:Phase 2
Title:Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
Status:Completed
updateDate:2010-08-20
Ctid:NCT01185418

Link: https://clinicaltrials.gov/ct2/show/NCT01185418

Conditions:Normal Volunteers
Interventions:lactose
Phase:
Title:Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis
Status:Unknown status
updateDate:2010-07-20
Ctid:NCT00983177

Link: https://clinicaltrials.gov/ct2/show/NCT00983177

Conditions:Calcific Tendonitis
Interventions:lactose
Phase:N/A
Title:Effects of Lactose on Fecal Microflora
Status:Completed
updateDate:2009-09-21
Ctid:NCT00599859

Link: https://clinicaltrials.gov/ct2/show/NCT00599859

Conditions:Lactose Intolerance
Interventions:lactose
Phase:N/A
Title:Deanxit and Rivotril in Tinnitus Patients
Status:Completed
updateDate:2009-08-11
Ctid:NCT00841230

Link: https://clinicaltrials.gov/ct2/show/NCT00841230

Conditions:Tinnitus
Interventions:Lactose placebo
Phase:Phase 4
Title:St. John's Wort in the Treatment of Raynaud's Phenomenon
Status:Completed
updateDate:2009-07-14
Ctid:NCT00351117

Link: https://clinicaltrials.gov/ct2/show/NCT00351117

Conditions:Raynaud's Disease
Interventions:Lactose
Phase:Phase 3
Title:Pharmacological Modulations of Allergen-Specific Immunotherapy
Status:Completed
updateDate:2008-04-11
Ctid:NCT00504946

Link: https://clinicaltrials.gov/ct2/show/NCT00504946

Conditions:Asthma
Interventions:lactose
Phase:Phase 3

相关产品
联系我们
电话: 020-31522723 传真: 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member